A new biotechnology startup is getting help from an unusual partner in its attempt to develop rare disease drugs that could also treat more common conditions. Actio Biosciences  which launched Tuesday with 55 million in venture funding is working with The Jackson Laboratory to engineer mouse models that better recapitulate diseases potentially allowing Actio scientists to more accurately vet would be drugs